TCRT Profile
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company specializing in oncology-focused cell therapies. The company is at the forefront of developing adoptive T-cell receptor (TCR) engineered therapies designed to target and treat various cancers. Its lead initiative, the TCR Library, is currently in Phase I/II clinical trials. This program utilizes a collection of ten TCRs specifically engineered to recognize mutated KRAS, TP53, and EGFR antigens. The TCR Library aims to address a range of malignancies, including non-small cell lung cancer, colorectal cancer, endometrial cancer, pancreatic cancer, ovarian cancer, and bile duct cancer.
Alaunos Therapeutics is also advancing its hunTR platform, which focuses on human neoantigen T-cell receptors. This innovative platform is designed to identify and target unique cancer antigens present in individual tumors, thereby enhancing the precision and effectiveness of immunotherapy. Additionally, the company is developing mbIL-15, a novel therapeutic approach intended to boost the immune response against solid tumors, further expanding its portfolio of cutting-edge cancer treatments.
The company has established significant collaborative agreements to advance its research and development efforts. It holds a license agreement with PGEN Therapeutics, Inc. and has research and development collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. These partnerships are instrumental in accelerating the development of its therapies and expanding its scientific and clinical knowledge base.
Originally known as ZIOPHARM Oncology, Inc., the company rebranded as Alaunos Therapeutics, Inc. in January 2022 to better reflect its focus on innovative cell therapy solutions. Headquartered in Houston, Texas, Alaunos Therapeutics continues to drive forward its mission of developing transformative treatments for cancer, leveraging its advanced technologies and strategic partnerships to improve patient outcomes in oncology.
|
